Matches in Nanopublications for { <http://bio2rdf.org/drugbank:DB05056> ?p ?o ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05056 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05056 label "EGS21 [drugbank:DB05056]" assertion.
- drugbank:DB05056 seeAlso DB05056 assertion.
- drugbank:DB05056 description "EGS21(TM) is a beta-D-glucosylceramide (GC) compound. It is a potential therapeutic for treating immune mediated disorders. GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate drug in the treatment of various immune mediated diseases, such as Crohn's disease, hepatitis, non-alcoholic steatohepatitis (NASH) or fatty liver and HIV." assertion.
- drugbank:DB05056 identifier "drugbank:DB05056" assertion.
- drugbank:DB05056 title "EGS21" assertion.
- drugbank:DB05056 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05056 drugbank_vocabulary:drugbank-id "DB05056" assertion.
- drugbank:DB05056 bio2rdf_vocabulary:x-identifiers.org DB05056 assertion.
- drugbank:DB05056 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05056" assertion.
- drugbank:DB05056 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05056 bio2rdf_vocabulary:identifier "DB05056" assertion.